Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robbie G Majzner
Cancer Immunotherapy Trials Network
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- British Columbia Children'S Hospital
Vancouver, British Columbia, Canada
- Hospital for Sick Children
Toronto, Ontario, Canada
- Children'S Hospital Los Angeles
Los Angeles, California, United States
- Lucile Packard Children'S Hospital Stanford University
Palo Alto, California, United States
- Ucsf Medical Center-Mission Bay
San Francisco, California, United States
- Children'S Hospital Colorado
Aurora, Colorado, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
- Baylor College of Medicine/dan L Duncan Comprehensive Cancer Center
Houston, Texas, United States
- Seattle Children'S Hospital
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2021
- Primary completion
- 30 Sept 2024
- Completion
- 30 Sept 2024
- Last update posted
- 30 Jun 2026
- Registered enrollment
- 12
- Registry id
- NCT04751383
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.